Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Holdings Increased by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 37.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 879,468 shares of the biotechnology company’s stock after buying an additional 241,279 shares during the period. Geode Capital Management LLC owned about 1.93% of Capricor Therapeutics worth $12,139,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after acquiring an additional 37,868 shares in the last quarter. Magnus Financial Group LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $276,000. JPMorgan Chase & Co. raised its holdings in Capricor Therapeutics by 419.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock worth $855,000 after buying an additional 45,381 shares during the period. State Street Corp raised its holdings in Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after buying an additional 111,291 shares during the period. Finally, Swiss National Bank purchased a new stake in Capricor Therapeutics during the fourth quarter valued at about $930,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Up 6.0 %

Capricor Therapeutics stock opened at $11.92 on Tuesday. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40. The stock has a market cap of $544.47 million, a P/E ratio of -11.25 and a beta of 4.65. The company’s fifty day simple moving average is $12.27 and its 200-day simple moving average is $14.96.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The firm had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. On average, equities research analysts expect that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CAPR. HC Wainwright restated a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.